Clinical Trials

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

Facing a cash crunch after a major clinical trial setback, the cancer vaccine developer is exploring a sale or merger, putting its pipeline at risk.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

A new grant funds a radical approach using AI and postmortem human brains to find crucial clues for Parkinson's therapies, aiming to crack a major medical challenge.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

Myriad Genetics is launching a new cancer test that promises to detect recurrence earlier than ever. But can it win in a competitive market?

An oral drug for Huntington's disease shows early success, improving patient scores where a decline was expected, fueling hope for a breakthrough treatment.

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

A new study confirms AI can detect major heart conditions from one brief ultrasound clip, empowering any clinician to perform life-saving cardiac screening.

With fresh funding, Primmune is advancing its unique TLR7 agonist, designed for efficacy without severe side effects, into a pivotal melanoma trial in Australia.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

A new strategic partnership aims to dismantle commercialization hurdles, promising faster access to life-saving therapies for rare disease patients.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

With a $150M+ capital raise and a top cancer immunologist on board, the T1D Fund is making a strategic play to shift from managing T1D to curing it.

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Carrying the Alzheimer's gene, a longevity expert has turned himself into a public experiment, documenting his radical protocol to prevent the disease.

The world's top cancer center partners with IBA in a multi-million dollar deal to install three advanced Proteus®ONE systems, heralding a new era.

Crosswalk Therapeutics secures a key grant to develop a therapy targeting the debilitating skeletal disease in Morquio A, a challenge current treatments can't solve.

Equinox's new EQX ARC program partners with Oura and Function to offer hyper-personalized, data-driven training for women across all life stages.